Splenic marginal zone lymphoma with or without villous lymphocytes

BACKGROUND Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, the minimal diagnostic data set, and therapy remain unanswered. METHODS Clinical‐pathologic features and outcomes of 57 consecutive patients who had s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2004-11, Vol.101 (9), p.2050-2057
Hauptverfasser: Iannitto, Emilio, Ambrosetti, Achille, Ammatuna, Emanuele, Colosio, Maura, Florena, Ada M., Tripodo, Claudio, Minardi, Viviana, Calvaruso, Giuseppina, Enza Mitra, Maria, Pizzolo, Giovanni, Menestrina, Fabio, Franco, Vito
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2057
container_issue 9
container_start_page 2050
container_title Cancer
container_volume 101
creator Iannitto, Emilio
Ambrosetti, Achille
Ammatuna, Emanuele
Colosio, Maura
Florena, Ada M.
Tripodo, Claudio
Minardi, Viviana
Calvaruso, Giuseppina
Enza Mitra, Maria
Pizzolo, Giovanni
Menestrina, Fabio
Franco, Vito
description BACKGROUND Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, the minimal diagnostic data set, and therapy remain unanswered. METHODS Clinical‐pathologic features and outcomes of 57 consecutive patients who had splenomegaly with no clinically significant lymphadenomegaly and who were diagnosed with SMZL with or without (±) villous lymphocytes (VL) were reviewed. RESULTS SMVL ± VL occurred mostly in elderly males (median age, 62 years ± 10 years; male‐to‐female ratio, (1.85). Anemia was recorded in 49% of patients, and 30% of patients had moderate thrombocytopenia. Leukocytosis and leukopenia were found in 33% and 14% of patients, respectively, and typical VL were found in 84% of patients. Serology for hepatitis C virus infection was positive in 16% of patients, and a small monoclonal component was detected in 36% of patients. The bone marrow was infiltrated with an intrasinusoidal component in all patients. Thirteen patients were monitored using a watch‐and‐see policy, and they remained alive 1–5 years after diagnosis. Overall, 21 patients (36%) underwent splenectomy; and, in all patients, the diagnosis of SMZL was confirmed histologically in the surgical specimens. Twenty‐five patients received single‐agent therapy, which included either alkylators or pentostatine, and they achieved an overall response rate (ORR) of 65% and 87%, respectively: Polychemotherapy was administered to 6 patients (ORR, 83%). The median survival for all patients in the series was not reached, and it is expected that 70% of patients will be alive at 5 years. CONCLUSIONS Up to 20% of patients who had SMZL ± VL could be monitored using a watch‐and‐wait policy. The bone marrow intrasinusoidal infiltration pattern may be a valuable diagnostic hallmark, thus obviating diagnostic splenectomy. The issues regarding prognostic stratification and the best therapeutic strategy need to be addressed in properly designed, prospective trials. Cancer 2004. © 2004 American Cancer Society. Splenic marginal zone lymphoma with or without villous lymphocytes is an indolent neoplasm, and up to 20% of patients require no therapy on diagnosis. The disease always involves bone marrow, although the infiltration may be very fine and exclusively intrasinusoidal. Bone marrow examination, coupled with the morphologic and immunophenotypic evaluation of peripheral blood, can lead to the correct diagnosis.
doi_str_mv 10.1002/cncr.20596
format Article
fullrecord <record><control><sourceid>wiley</sourceid><recordid>TN_cdi_wiley_primary_10_1002_cncr_20596_CNCR20596</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CNCR20596</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1196-3b550cdcee42442553f0d618701173258eee8352affc8a2bf1b9f4e2338b61383</originalsourceid><addsrcrecordid>eNotj9tKw0AYhBdRMFZvfIJ9gdT_30OyudSgVigKHsC7ZbPdtSubA0lqiU9vW3s1MzAM8xFyjTBHAHZjG9vPGcgiOyEJQpGngIKdkgQAVCoF_zwnF8PwvYs5kzwhd29ddE2wtDb9V2hMpL9t42ic6m7d1oZuw7imbX_QdjPSnxBjuxmOBTuNbrgkZ97EwV0ddUY-Hu7fy0W6fHl8Km-XqUUsspRXUoJdWecEE4JJyT2sMlQ5IOacSeWcU1wy471VhlUeq8ILxzhXVYZc8RnB_91tiG7SXR92nyeNoPfoeo-uD-i6fC5fD47_AbNVT3I</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Splenic marginal zone lymphoma with or without villous lymphocytes</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Iannitto, Emilio ; Ambrosetti, Achille ; Ammatuna, Emanuele ; Colosio, Maura ; Florena, Ada M. ; Tripodo, Claudio ; Minardi, Viviana ; Calvaruso, Giuseppina ; Enza Mitra, Maria ; Pizzolo, Giovanni ; Menestrina, Fabio ; Franco, Vito</creator><creatorcontrib>Iannitto, Emilio ; Ambrosetti, Achille ; Ammatuna, Emanuele ; Colosio, Maura ; Florena, Ada M. ; Tripodo, Claudio ; Minardi, Viviana ; Calvaruso, Giuseppina ; Enza Mitra, Maria ; Pizzolo, Giovanni ; Menestrina, Fabio ; Franco, Vito</creatorcontrib><description>BACKGROUND Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, the minimal diagnostic data set, and therapy remain unanswered. METHODS Clinical‐pathologic features and outcomes of 57 consecutive patients who had splenomegaly with no clinically significant lymphadenomegaly and who were diagnosed with SMZL with or without (±) villous lymphocytes (VL) were reviewed. RESULTS SMVL ± VL occurred mostly in elderly males (median age, 62 years ± 10 years; male‐to‐female ratio, (1.85). Anemia was recorded in 49% of patients, and 30% of patients had moderate thrombocytopenia. Leukocytosis and leukopenia were found in 33% and 14% of patients, respectively, and typical VL were found in 84% of patients. Serology for hepatitis C virus infection was positive in 16% of patients, and a small monoclonal component was detected in 36% of patients. The bone marrow was infiltrated with an intrasinusoidal component in all patients. Thirteen patients were monitored using a watch‐and‐see policy, and they remained alive 1–5 years after diagnosis. Overall, 21 patients (36%) underwent splenectomy; and, in all patients, the diagnosis of SMZL was confirmed histologically in the surgical specimens. Twenty‐five patients received single‐agent therapy, which included either alkylators or pentostatine, and they achieved an overall response rate (ORR) of 65% and 87%, respectively: Polychemotherapy was administered to 6 patients (ORR, 83%). The median survival for all patients in the series was not reached, and it is expected that 70% of patients will be alive at 5 years. CONCLUSIONS Up to 20% of patients who had SMZL ± VL could be monitored using a watch‐and‐wait policy. The bone marrow intrasinusoidal infiltration pattern may be a valuable diagnostic hallmark, thus obviating diagnostic splenectomy. The issues regarding prognostic stratification and the best therapeutic strategy need to be addressed in properly designed, prospective trials. Cancer 2004. © 2004 American Cancer Society. Splenic marginal zone lymphoma with or without villous lymphocytes is an indolent neoplasm, and up to 20% of patients require no therapy on diagnosis. The disease always involves bone marrow, although the infiltration may be very fine and exclusively intrasinusoidal. Bone marrow examination, coupled with the morphologic and immunophenotypic evaluation of peripheral blood, can lead to the correct diagnosis.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.20596</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>bone marrow biopsy ; intrasinusoidal ; splenectomy ; splenic lymphoma with villous lymphocytes ; splenic marginal zone lymphoma</subject><ispartof>Cancer, 2004-11, Vol.101 (9), p.2050-2057</ispartof><rights>Copyright © 2004 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1196-3b550cdcee42442553f0d618701173258eee8352affc8a2bf1b9f4e2338b61383</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.20596$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.20596$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids></links><search><creatorcontrib>Iannitto, Emilio</creatorcontrib><creatorcontrib>Ambrosetti, Achille</creatorcontrib><creatorcontrib>Ammatuna, Emanuele</creatorcontrib><creatorcontrib>Colosio, Maura</creatorcontrib><creatorcontrib>Florena, Ada M.</creatorcontrib><creatorcontrib>Tripodo, Claudio</creatorcontrib><creatorcontrib>Minardi, Viviana</creatorcontrib><creatorcontrib>Calvaruso, Giuseppina</creatorcontrib><creatorcontrib>Enza Mitra, Maria</creatorcontrib><creatorcontrib>Pizzolo, Giovanni</creatorcontrib><creatorcontrib>Menestrina, Fabio</creatorcontrib><creatorcontrib>Franco, Vito</creatorcontrib><title>Splenic marginal zone lymphoma with or without villous lymphocytes</title><title>Cancer</title><description>BACKGROUND Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, the minimal diagnostic data set, and therapy remain unanswered. METHODS Clinical‐pathologic features and outcomes of 57 consecutive patients who had splenomegaly with no clinically significant lymphadenomegaly and who were diagnosed with SMZL with or without (±) villous lymphocytes (VL) were reviewed. RESULTS SMVL ± VL occurred mostly in elderly males (median age, 62 years ± 10 years; male‐to‐female ratio, (1.85). Anemia was recorded in 49% of patients, and 30% of patients had moderate thrombocytopenia. Leukocytosis and leukopenia were found in 33% and 14% of patients, respectively, and typical VL were found in 84% of patients. Serology for hepatitis C virus infection was positive in 16% of patients, and a small monoclonal component was detected in 36% of patients. The bone marrow was infiltrated with an intrasinusoidal component in all patients. Thirteen patients were monitored using a watch‐and‐see policy, and they remained alive 1–5 years after diagnosis. Overall, 21 patients (36%) underwent splenectomy; and, in all patients, the diagnosis of SMZL was confirmed histologically in the surgical specimens. Twenty‐five patients received single‐agent therapy, which included either alkylators or pentostatine, and they achieved an overall response rate (ORR) of 65% and 87%, respectively: Polychemotherapy was administered to 6 patients (ORR, 83%). The median survival for all patients in the series was not reached, and it is expected that 70% of patients will be alive at 5 years. CONCLUSIONS Up to 20% of patients who had SMZL ± VL could be monitored using a watch‐and‐wait policy. The bone marrow intrasinusoidal infiltration pattern may be a valuable diagnostic hallmark, thus obviating diagnostic splenectomy. The issues regarding prognostic stratification and the best therapeutic strategy need to be addressed in properly designed, prospective trials. Cancer 2004. © 2004 American Cancer Society. Splenic marginal zone lymphoma with or without villous lymphocytes is an indolent neoplasm, and up to 20% of patients require no therapy on diagnosis. The disease always involves bone marrow, although the infiltration may be very fine and exclusively intrasinusoidal. Bone marrow examination, coupled with the morphologic and immunophenotypic evaluation of peripheral blood, can lead to the correct diagnosis.</description><subject>bone marrow biopsy</subject><subject>intrasinusoidal</subject><subject>splenectomy</subject><subject>splenic lymphoma with villous lymphocytes</subject><subject>splenic marginal zone lymphoma</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNotj9tKw0AYhBdRMFZvfIJ9gdT_30OyudSgVigKHsC7ZbPdtSubA0lqiU9vW3s1MzAM8xFyjTBHAHZjG9vPGcgiOyEJQpGngIKdkgQAVCoF_zwnF8PwvYs5kzwhd29ddE2wtDb9V2hMpL9t42ic6m7d1oZuw7imbX_QdjPSnxBjuxmOBTuNbrgkZ97EwV0ddUY-Hu7fy0W6fHl8Km-XqUUsspRXUoJdWecEE4JJyT2sMlQ5IOacSeWcU1wy471VhlUeq8ILxzhXVYZc8RnB_91tiG7SXR92nyeNoPfoeo-uD-i6fC5fD47_AbNVT3I</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>Iannitto, Emilio</creator><creator>Ambrosetti, Achille</creator><creator>Ammatuna, Emanuele</creator><creator>Colosio, Maura</creator><creator>Florena, Ada M.</creator><creator>Tripodo, Claudio</creator><creator>Minardi, Viviana</creator><creator>Calvaruso, Giuseppina</creator><creator>Enza Mitra, Maria</creator><creator>Pizzolo, Giovanni</creator><creator>Menestrina, Fabio</creator><creator>Franco, Vito</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope/></search><sort><creationdate>20041101</creationdate><title>Splenic marginal zone lymphoma with or without villous lymphocytes</title><author>Iannitto, Emilio ; Ambrosetti, Achille ; Ammatuna, Emanuele ; Colosio, Maura ; Florena, Ada M. ; Tripodo, Claudio ; Minardi, Viviana ; Calvaruso, Giuseppina ; Enza Mitra, Maria ; Pizzolo, Giovanni ; Menestrina, Fabio ; Franco, Vito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1196-3b550cdcee42442553f0d618701173258eee8352affc8a2bf1b9f4e2338b61383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>bone marrow biopsy</topic><topic>intrasinusoidal</topic><topic>splenectomy</topic><topic>splenic lymphoma with villous lymphocytes</topic><topic>splenic marginal zone lymphoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iannitto, Emilio</creatorcontrib><creatorcontrib>Ambrosetti, Achille</creatorcontrib><creatorcontrib>Ammatuna, Emanuele</creatorcontrib><creatorcontrib>Colosio, Maura</creatorcontrib><creatorcontrib>Florena, Ada M.</creatorcontrib><creatorcontrib>Tripodo, Claudio</creatorcontrib><creatorcontrib>Minardi, Viviana</creatorcontrib><creatorcontrib>Calvaruso, Giuseppina</creatorcontrib><creatorcontrib>Enza Mitra, Maria</creatorcontrib><creatorcontrib>Pizzolo, Giovanni</creatorcontrib><creatorcontrib>Menestrina, Fabio</creatorcontrib><creatorcontrib>Franco, Vito</creatorcontrib><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iannitto, Emilio</au><au>Ambrosetti, Achille</au><au>Ammatuna, Emanuele</au><au>Colosio, Maura</au><au>Florena, Ada M.</au><au>Tripodo, Claudio</au><au>Minardi, Viviana</au><au>Calvaruso, Giuseppina</au><au>Enza Mitra, Maria</au><au>Pizzolo, Giovanni</au><au>Menestrina, Fabio</au><au>Franco, Vito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Splenic marginal zone lymphoma with or without villous lymphocytes</atitle><jtitle>Cancer</jtitle><date>2004-11-01</date><risdate>2004</risdate><volume>101</volume><issue>9</issue><spage>2050</spage><epage>2057</epage><pages>2050-2057</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>BACKGROUND Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, the minimal diagnostic data set, and therapy remain unanswered. METHODS Clinical‐pathologic features and outcomes of 57 consecutive patients who had splenomegaly with no clinically significant lymphadenomegaly and who were diagnosed with SMZL with or without (±) villous lymphocytes (VL) were reviewed. RESULTS SMVL ± VL occurred mostly in elderly males (median age, 62 years ± 10 years; male‐to‐female ratio, (1.85). Anemia was recorded in 49% of patients, and 30% of patients had moderate thrombocytopenia. Leukocytosis and leukopenia were found in 33% and 14% of patients, respectively, and typical VL were found in 84% of patients. Serology for hepatitis C virus infection was positive in 16% of patients, and a small monoclonal component was detected in 36% of patients. The bone marrow was infiltrated with an intrasinusoidal component in all patients. Thirteen patients were monitored using a watch‐and‐see policy, and they remained alive 1–5 years after diagnosis. Overall, 21 patients (36%) underwent splenectomy; and, in all patients, the diagnosis of SMZL was confirmed histologically in the surgical specimens. Twenty‐five patients received single‐agent therapy, which included either alkylators or pentostatine, and they achieved an overall response rate (ORR) of 65% and 87%, respectively: Polychemotherapy was administered to 6 patients (ORR, 83%). The median survival for all patients in the series was not reached, and it is expected that 70% of patients will be alive at 5 years. CONCLUSIONS Up to 20% of patients who had SMZL ± VL could be monitored using a watch‐and‐wait policy. The bone marrow intrasinusoidal infiltration pattern may be a valuable diagnostic hallmark, thus obviating diagnostic splenectomy. The issues regarding prognostic stratification and the best therapeutic strategy need to be addressed in properly designed, prospective trials. Cancer 2004. © 2004 American Cancer Society. Splenic marginal zone lymphoma with or without villous lymphocytes is an indolent neoplasm, and up to 20% of patients require no therapy on diagnosis. The disease always involves bone marrow, although the infiltration may be very fine and exclusively intrasinusoidal. Bone marrow examination, coupled with the morphologic and immunophenotypic evaluation of peripheral blood, can lead to the correct diagnosis.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><doi>10.1002/cncr.20596</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2004-11, Vol.101 (9), p.2050-2057
issn 0008-543X
1097-0142
language eng
recordid cdi_wiley_primary_10_1002_cncr_20596_CNCR20596
source Wiley Free Content; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects bone marrow biopsy
intrasinusoidal
splenectomy
splenic lymphoma with villous lymphocytes
splenic marginal zone lymphoma
title Splenic marginal zone lymphoma with or without villous lymphocytes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T08%3A50%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Splenic%20marginal%20zone%20lymphoma%20with%20or%20without%20villous%20lymphocytes&rft.jtitle=Cancer&rft.au=Iannitto,%20Emilio&rft.date=2004-11-01&rft.volume=101&rft.issue=9&rft.spage=2050&rft.epage=2057&rft.pages=2050-2057&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.20596&rft_dat=%3Cwiley%3ECNCR20596%3C/wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true